Tier 2 — strong

Effect of quercetin on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease

Natalia I Chekalina, Svitlana V Shut, Tetiana A Trybrat, Yurii H Burmak, Yeuhen Ye Petrov, Yulia I Manusha, Yurii M Kazakov
Wiadomosci lekarskie (Warsaw, Poland : 1960) 2017 70(4):707

Bibliography

PubMed
PMID 29064791
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized adjunctive usual-care controlled trial
ModelHuman intervention research
Sample85 adults with stable coronary disease: 30 quercetin and 55 comparison; 30 healthy reference subjects
InterventionOral quercetin 120 mg/day added to standard treatment
Duration2 months after a stabilization phase
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2017, this source examined cardiovascular and metabolic health. Design: Randomized adjunctive usual-care controlled trial. Sample/model: 85 adults with stable coronary disease: 30 quercetin and 55 comparison; 30 healthy reference subjects. The exposure or intervention was Oral quercetin 120 mg/day added to standard treatment. Follow-up or treatment period: 2 months after a stabilization phase.

Some ischemia, ectopic-beat and diastolic measurements favored added quercetin, while both patient groups improved on several measures.

Unequal groups, limited masking information and surrogate outcomes. Cardiovascular-event reduction was not established.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Some ischemia, ectopic-beat and diastolic measurements favored added quercetin, while both patient groups improved on several measures.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Oral quercetin 120 mg/day added to standard treatment; 2 months after a stabilization phase.

What this study can and cannot tell us

  • Unequal groups, limited masking information and surrogate outcomes. Cardiovascular-event reduction was not established.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology